Mounjaro vs Wegovy vs Ozempic in India — An Endocrinologist's Honest Comparison (2026)

What GLP-1 Drugs Actually Do

Before we compare these three medications, it's worth understanding what all of them have in common — and why they represent a genuine revolution in metabolic medicine rather than just another class of diabetes drugs.

GLP-1 stands for glucagon-like peptide-1 — a naturally occurring hormone produced in the gut in response to eating. It has three primary actions that make it extraordinary from a therapeutic standpoint:

1. Glucose-dependent insulin stimulation: GLP-1 tells the pancreas to release insulin — but only when blood glucose is elevated. This means these drugs essentially cannot cause hypoglycaemia on their own, unlike sulphonylureas or insulin. They only lower glucose when glucose is high.
2. Glucagon suppression: GLP-1 suppresses glucagon — the hormone that tells the liver to release stored glucose. In Type 2 diabetes, glucagon is often inappropriately elevated, driving high fasting glucose. GLP-1 drugs directly address this.
3. Appetite suppression and gastric slowing: GLP-1 receptors in the brain — particularly in the hypothalamus — reduce appetite and food cravings. GLP-1 also slows gastric emptying, meaning food stays in the stomach longer, producing prolonged satiety. This is the mechanism behind significant weight loss.

The incretin effect — the amplification of insulin release by gut hormones — is significantly blunted in Type 2 diabetes. GLP-1 receptor agonists essentially restore this effect pharmacologically, while simultaneously addressing the brain-based appetite dysregulation that drives obesity. This is why they work so powerfully on both blood sugar and weight simultaneously.

Ozempic (Semaglutide 1mg): The Established Diabetes Drug

Ozempic was the drug that introduced most of the world to GLP-1 therapy. Approved for Type 2 diabetes management, it has been used globally since 2017 and has the largest real-world evidence base of the three drugs we're discussing today.

What It Is and How It Works

Ozempic contains semaglutide — a synthetic GLP-1 receptor agonist — at a maximum dose of 1mg weekly by subcutaneous injection. It was engineered with a fatty acid side chain that binds to albumin in the bloodstream, dramatically extending its half-life to approximately 7 days, making once-weekly dosing possible.

Efficacy Data

From the SUSTAIN clinical trial programme, Ozempic at 1mg demonstrates:

• HbA1c reduction: approximately 1.5 percentage points from baseline
• Weight loss: approximately 4–6 kg (roughly 5–6% of body weight) over 30 weeks
• Cardiovascular benefit: SUSTAIN-6 demonstrated significant reduction in major adverse cardiovascular events (MACE) — the first GLP-1 trial to demonstrate cardiovascular risk reduction
• Blood pressure: modest reduction in systolic BP of approximately 3–5 mmHg

India Cost and Availability (2026)

Ozempic is the most established and reliably available of the three drugs in India. Estimated monthly cost: ₹6,000–9,000 for 1mg weekly dose (0.25mg and 0.5mg starting doses are less expensive). Available at major pharmacy chains and through hospital pharmacies. Novo Nordisk (the manufacturer) has maintained reasonably consistent supply.

Who Is Ozempic For?

Ozempic is the appropriate choice for patients with Type 2 diabetes who need improved HbA1c control with some weight loss benefit, who have cardiovascular disease or risk factors, and for whom cost is a consideration over the more powerful alternatives.

Wegovy (Semaglutide 2.4mg): The Weight Loss Version

Wegovy contains the exact same molecule as Ozempic — semaglutide — but at a substantially higher dose (2.4mg vs 1mg) and with a different regulatory approval: it is approved specifically for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity, regardless of diabetes status.

Why the Higher Dose Matters

The dose-response relationship for semaglutide's weight loss effects is steep — the jump from 1mg to 2.4mg delivers significantly more appetite suppression and gastric slowing. This is not a linear relationship: the 2.4mg dose achieves approximately 2.5× more weight loss than the 1mg dose, even though the increase in dose is only 2.4×.

STEP Trial Data

The STEP clinical trial programme established Wegovy's remarkable efficacy:

• Average weight loss: 14.9% of body weight at 68 weeks (STEP-1 trial) — approximately 15 kg for a 100 kg patient
• Responders (≥5% weight loss): 86% of participants
• Responders (≥15% weight loss): 32% of participants
• Cardiovascular benefit: SELECT trial (2023) demonstrated 20% reduction in MACE in non-diabetic obese patients — a landmark result that expanded the indication far beyond diabetes

India Availability and Cost (2026)

Wegovy's availability in India remains limited compared to Ozempic. Novo Nordisk has been prioritising supply for markets where it has formal approval, and India's regulatory status for the obesity indication is still evolving. Where available, estimated cost: ₹10,000–16,000/month at the maintenance dose. Some patients access it through private importation, which requires careful sourcing to ensure authenticity.

Mounjaro (Tirzepatide): The Game-Changer

If Ozempic was the revolution, Mounjaro (tirzepatide) is the next step beyond it. Developed by Eli Lilly and approved by the FDA in 2022 for Type 2 diabetes and in 2023 for obesity (as Zepbound), tirzepatide introduced a genuinely new mechanism: it is the world's first dual GIP and GLP-1 receptor agonist.

The Dual Mechanism Advantage

GIP (glucose-dependent insulinotropic polypeptide) is the other major incretin hormone — produced earlier in the digestive process and with a somewhat different receptor distribution. In Type 2 diabetes, GIP signalling is impaired in the pancreas but actually enhanced in fat tissue, promoting fat storage. Tirzepatide's simultaneous activation of both GIP and GLP-1 receptors creates a synergistic effect: better glucose lowering, greater weight loss, and potentially more direct effects on fat metabolism than GLP-1 alone.

SURPASS Trial Data (Diabetes)

From the SURPASS clinical programme:

• HbA1c reduction: 2.0–2.5 percentage points at the 15mg dose — the most powerful glucose lowering of any non-insulin agent ever tested
• Weight loss: 8–11 kg in patients with Type 2 diabetes (significant weight loss even in a population not primarily selected for obesity)
• HbA1c below 7% achievement: up to 92% of patients on 15mg reached HbA1c below 7% — a remarkable outcome

SURMOUNT Trial Data (Obesity)

From the SURMOUNT-1 trial in non-diabetic obese adults:

• Average weight loss at 72 weeks: 20.9% of body weight at 15mg dose
• Responders (≥20% weight loss): 57% of participants
• Responders (≥25% weight loss): 36% — approaching surgical weight loss territory

India Availability and Cost (2026)

Tirzepatide became available in India in 2025 and is now accessible through specialist endocrinologists and hospital pharmacies. Estimated monthly cost: ₹8,000–12,000 for 5mg weekly dose, ₹14,000–18,000 for 15mg weekly dose. A prescription from a specialist is required. At Gini Hospital, we prescribe tirzepatide for eligible patients and provide the monitoring structure needed for safe titration.

Direct Comparison: Who Should Choose Which?

The honest answer is: there is no universally "best" GLP-1 drug. The right choice depends on your individual clinical profile. Here is the data side-by-side, followed by my clinical recommendations by patient type.

My Clinical Recommendations by Patient Type

Patient: Type 2 diabetes, HbA1c 8–10, BMI 25–30, cardiovascular risk factors, cost-conscious
Recommended: Ozempic (semaglutide 1mg). Proven cardiovascular benefit, good HbA1c reduction, most affordable and reliably available option in India.

Patient: Obesity (BMI ≥30) without diabetes, primary goal is weight loss
Recommended: Wegovy (2.4mg) if available, or tirzepatide (Mounjaro). The higher dose of semaglutide delivers substantially more weight loss. If Wegovy availability is uncertain, Mounjaro is the superior alternative with even greater efficacy.

Patient: Type 2 diabetes, HbA1c above 9, significant obesity (BMI ≥30), wants maximum effect
Recommended: Mounjaro (tirzepatide) — the most powerful dual mechanism drug, delivering the best HbA1c reduction and the highest weight loss simultaneously. This is the patient who benefits most from tirzepatide's dual mechanism.

Patient: Well-controlled diabetes, moderate weight, primarily wants weight loss of 10–15%
Recommended: Either Wegovy or Mounjaro — both deliver significantly more weight loss than Ozempic. Clinical assessment needed to determine which is more appropriate.

Side Effects, Safety, and What to Expect in the First Weeks

GLP-1 drugs are generally well-tolerated, but the first 4–8 weeks of treatment — particularly during dose escalation — involve a predictable set of gastrointestinal side effects that patients need to be prepared for. Understanding and managing these early side effects is the difference between patients who succeed on these drugs and those who stop prematurely.

Common Side Effects (All Three Drugs)

• Nausea (40–50% of patients): The most common side effect. Worst in weeks 2–6 as the dose is being titrated. Typically manageable with small, frequent meals and avoiding fatty or spicy food. Severe in ~10% of patients.
• Vomiting (~20%): Usually accompanies severe nausea. If persistent, dose titration should be slowed.
• Constipation or diarrhoea (15–20%): Gastric slowing (from GLP-1 effect) tends to cause constipation; the vagal stimulation can cause diarrhoea in some patients. Hydration and dietary fibre help.
• Reduced appetite: This is the therapeutic effect — but some patients experience it as uncomfortable food aversion early in treatment.
• Injection site reactions: Minor redness or bruising, rare with correct technique.

Serious but Rare Side Effects

• Pancreatitis: Rare but serious. Stop the medication and seek immediate medical attention if you experience severe, persistent abdominal pain. Contraindicated in patients with a history of pancreatitis.
• Gallstones: Rapid weight loss increases gallstone risk. Monitor with ultrasound if symptomatic.
• Thyroid C-cell tumours: Observed in rodent studies at very high doses. The FDA and EMA warn against use in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 (MEN2). No confirmed cases in humans at clinical doses.

Who Should NOT Use GLP-1 Drugs

• Personal or family history of medullary thyroid cancer or MEN2
• History of pancreatitis
• Severe gastroparesis (GLP-1 drugs slow gastric emptying further)
• Pregnancy or breastfeeding
• Type 1 diabetes (GLP-1 drugs are not primary therapy for T1D)

Practical Guide to Starting GLP-1 Therapy in India

If you and your doctor have decided that GLP-1 therapy is appropriate for you, here is what you need to know to start successfully in the Indian context.

Getting a Prescription

All three medications require a doctor's prescription in India. Self-sourcing without medical supervision is strongly discouraged — not only for safety reasons, but because the titration schedule, monitoring requirements, and management of side effects all require clinical expertise. At Gini Hospital, Dr. Bhansali and his team conduct a full metabolic assessment before prescribing any GLP-1 agent.

Titration Schedule (Why It Matters)

GLP-1 therapy is always started at the lowest dose and escalated slowly over months. This titration schedule exists to minimise nausea and allow the gut to adapt. Patients who rush the titration have far worse side effects and are more likely to stop treatment. A typical tirzepatide schedule: 2.5mg for 4 weeks, then 5mg for 4 weeks, then escalate by 2.5mg every 4 weeks as tolerated. Maintenance dose is often 10–15mg, but many patients find 5–7.5mg provides excellent results with fewer side effects.

Storage

All three drugs require refrigeration at 2–8°C. They can be kept at room temperature (below 30°C) for up to 56 days after first use (Ozempic/Wegovy) or up to 21 days (Mounjaro). Do not freeze. Keep away from direct sunlight. When travelling, use an insulated pouch with ice packs.

Injection Technique

All three are once-weekly subcutaneous injections — into the abdomen, upper thigh, or upper arm. Rotate injection sites each week. Use a new needle for each injection. The pen devices are pre-filled and designed for patient self-injection with minimal training. Dr. Bhansali's team demonstrates injection technique to all new patients at Gini Hospital.

Monitoring Required

While on GLP-1 therapy, patients at Gini Hospital are monitored with:

• HbA1c every 3 months for the first year
• Weight and BMI at every visit
• Kidney function (eGFR, urine ACR) every 6 months
• Lipid panel annually
• Blood pressure at every visit
• Abdominal ultrasound if gallbladder symptoms develop

Realistic Cost Planning

GLP-1 therapy is a significant monthly expense in India. For context:

• Ozempic: ₹6,000–9,000/month (lowest cost, most available)
• Mounjaro 5mg: ₹8,000–12,000/month (often the starting and effective dose)
• Mounjaro 10–15mg: ₹14,000–20,000/month (maintenance/maximum dose)

At Gini Hospital, we work with patients to find the minimum effective dose — which often means patients achieve excellent results at 5–7.5mg tirzepatide rather than the 15mg maximum dose used in trials. This can reduce costs significantly while maintaining most of the benefit.